Radiation Dosimetry of 18F-FPEB in Humans

被引：12

作者：

Kessler, Robert M. ^{[1
]}

Seibyl, John ^{[2
]}

Cowan, Ronald L. ^{[1
]}

Zald, David ^{[3
]}

Young, Jacob S. ^{[3
]}

Ansari, Mohammad Sib ^{[1
]}

Stabin, Michael G. ^{[1
]}

机构：

[1] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA

[2] Inst Neurodegenerat Disorders, New Haven, CT USA

[3] Vanderbilt Univ, Sch Arts & Sci, Nashville, TN 37235 USA

来源：

JOURNAL OF NUCLEAR MEDICINE | 2014年 / 55卷 / 07期

关键词：

F-18-FPEB; glutamate; mGluR5; radiation dosimetry; INTERNAL DOSE ASSESSMENT; GLUTAMATE-RECEPTOR; 5; MGLUR5; BEHAVIORS; BINDING; MODELS; MICE; PET;

D O I：

10.2967/jnumed.113.133843

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

F-18-3-fluoro-5-[(pyridin-3-yl)ethynylibenzonitrile (F-18-FPEB) is a potent and specific radioligand for the metabotropic glutamate receptor subtype 5 (mGluR5). Before undertaking clinical research studies with F-18-FPEB, we performed studies of human radiation dosimetry. Methods: Serial whole-body scans were obtained in 9 healthy human subjects (5 men, 4 women) for 190-440 min after the intravenous administration of F-18-FPEB. Radiation doses were estimated using the OLINDA/EXM software. Results: Peak organ doses were to the urinary bladder wall, 0.258 mGy/MBq (0.955 rad/mCi), and gallbladder wall, 0.193 mGy/MBq (0.716 rad/mCi). The effective dose was 0.025 mSv/MBq (0.0922 rem/mCi). The doses to the red marrow and spleen were 0.00797 mGy/MBq (0.0295 rad/mCi) and 0.00709 mGy/MBq (0.0262 rad/mCi), respectively. Reducing the urinary voiding interval to 60 or 90 min lowered the urinary bladder wall dose to 0.0885 mGy/MBq (0.327 rad/mCi) or 0.128 mGy/MBq (0.473 rad/mCi), respectively, and the effective dose to 0.0149 mSv/MBq (0.0551 rem/mCi) or 0.0171 mSv/MBq (0.0634 rem/mCi), respectively. Conclusion: Urinary voiding should be performed during F-18-FPEB studies to minimize radiation exposure to research subjects.

引用

页码：1119 / 1121

页数：3

共 18 条

[1] Inhibition of metabotropic glutamate receptor signaling by the huntingtin-binding protein optineurin [J].